Stats-Secretary, Deputy Head of Federal Antimonopoly Service of Russian Federation, Andrey Tsarikovskiy, recently has discussed specifics of state regulation in the medicine market and shared Russian experience in it.
There was a gathering of the Round Table in Minsk on the topic of “Common market of medicines. Reference pricing” on the 28th February, 2019, seeking to exchange experience and practices of the market regulation.
Andrey Tsarikovskiy noticed that on the 27th February, the Agreement on Cooperation for the competition protection was signed in Moscow between the Government of the Russian Federation and the Government of Belarus.
Stats-Secretary said: “This is an intergovernmental Agreement and its compliance is mandatory for all market players. The Agreement provides, in particular, for joint investigations, especially of such dangerous economic violations as cartels as a result of which high prices for goods are fixed and maintained”.
While bringing on topic of Russia experience in pharmaceutical market regulation, Deputy Head of FAS emphasized that this market strongly affects the population.
“The complexity of regulating the medicine market is the need to achieve a hard combination: it is necessary that all medicinal drugs pass all clinical trials and are on sale at reasonable prices but at the same time there should be competition on the market. These are often opposing tasks”, explained Andrey Tsarikovskiy and stated also: “We moved ahead in this direction: FAS introduced the principle of reference pricing when we compare Russian prices with drug prices in other countries”.
He concluded: “We have managed to streamline and make such pricing clear, which, in its turn, develop competition on the market, provided that the volume of supplied medicines is maintained”.